Author: Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
Title: Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens Document date: 2019_9_5
ID: 4cia91cq_30
Snippet: Marburg hemorrhagic fever, caused by Marburg virus (MARV) of the genus Marburgvirus, is characterized by its high casefatality rate. Also belonging to the family of Filoviridae, MARV shares a lot of characteristics with EBOV. However, historically less frequent outbreaks with fewer affected individuals have occurred. 86 It both poses a great potential public health threat as an emerging virus and is listed as a category A bioterrorism agent by th.....
Document: Marburg hemorrhagic fever, caused by Marburg virus (MARV) of the genus Marburgvirus, is characterized by its high casefatality rate. Also belonging to the family of Filoviridae, MARV shares a lot of characteristics with EBOV. However, historically less frequent outbreaks with fewer affected individuals have occurred. 86 It both poses a great potential public health threat as an emerging virus and is listed as a category A bioterrorism agent by the Center for Disease Control (CDC), making vaccine development a priority. Despite decades of research, no licensed vaccines or therapies are available to date. However, ample preclinical data on rVSV-vectored MARV vaccine candidates have been generatedoften alongside the EBOV vaccine candidates, both as a pre-exposure prophylactic as well as a postexposure vaccine (reviewed in 15, 87, 88 ).
Search related documents:
Co phrase search for related documents- bioterrorism agent and vaccine development: 1, 2
- bioterrorism agent and vaccine development priority: 1
- casefatality rate and vaccine candidate: 1, 2
- casefatality rate and vaccine development: 1
- casefatality rate and vaccine development priority: 1
- EBOV vaccine candidate and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- EBOV vaccine candidate and vaccine development: 1, 2, 3, 4, 5
- EBOV vaccine candidate and vaccine development priority: 1
- emerge virus and vaccine development: 1, 2, 3, 4, 5
- Filoviridae family and vaccine candidate: 1
- Filoviridae family and vaccine development: 1, 2, 3, 4, 5
- Filoviridae family and vaccine development priority: 1
- hemorrhagic fever and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- hemorrhagic fever and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- hemorrhagic fever and vaccine development priority: 1
- high casefatality rate and vaccine candidate: 1
- high casefatality rate and vaccine development: 1
- high casefatality rate and vaccine development priority: 1
- licensed vaccine and therapy licensed vaccine: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date